Study Identifies HER2 Expression as Potential Target in Rare Sarcoma Patients
A retrospective study of eleven patients with desmoplastic small round cell tumors found HER2 protein expression without gene amplification and ...
Tag: antibody-drug conjugates
Study Finds Antibody–Drug Conjugate Safety Profiles Differ by Platform and Target
A retrospective pharmacovigilance study of 38,371 FAERS reports across 13 approved antibody–drug conjugates found that linker-payload platforms and target antigens ...
Zolbetuximab Improves Survival in CLDN18.2-Positive, HER2-Negative Gastric Cancer, Review Reports
A medical review examines advances in targeted therapies and immunotherapies, including zolbetuximab, for patients with CLDN18.2-positive advanced gastric or gastroesophageal ...
Tumor Organoids Bridge Preclinical Models and Precision Oncology in New Clinical Review
A scientific review in Clinical and Experimental Medicine highlights how patient-derived tumor organoids bridge preclinical models and clinical oncology while ...
Deep Learning Predicts HER2-Low Breast Cancer Status From Routine Slide Images
A retrospective deep learning framework analyzing routine hematoxylin and eosin stained whole-slide images has achieved a mean area under the ...
High Tissue Factor Levels Identify Poor Prognosis in Esophageal Adenocarcinoma
A retrospective cohort study reveals that high tissue factor expression marks an aggressive subgroup of esophageal and esophagogastric junction adenocarcinomas ...
Sacituzumab Govitecan and TRAIL Agonists Show Synergistic Lethality in Preclinical Breast Cancer
Preclinical experiments demonstrate that combining the Trop2-directed antibody-drug conjugate sacituzumab govitecan with TRAIL agonists produces synergistic, caspase-dependent apoptotic cell death ...
Study Identifies Cell Surface Targets Linked to Treatment Resistant Breast Cancer
A comprehensive genomic analysis of thousands of early-stage breast cancer tumors reveals alternative cell surface targets associated with treatment resistance ...
Regulators and Industry Face Complex Payload Disposition Challenges Across Fifteen Oncology ADCs
A comprehensive review of fifteen approved antibody-drug conjugates highlights diverse industry strategies and regulatory hurdles in evaluating the metabolic disposition, ...
Antibody-Drug Conjugates Face Clinical Resistance and Toxicity Challenges in Solid Tumors
A review in Molecular Cancer examines how antibody-drug conjugates treat solid tumors while addressing clinical resistance, toxicity profiles, and narrow ...
PET/CT imaging reveals metabolic differences across HER2-low, HER2-zero and HER2-overexpressing breast cancers
A retrospective study of 248 breast cancer patients found that HER2-low, HER2-zero, and HER2-overexpressing tumors show distinct glucose metabolism patterns ...
FDA-Approved Antibody-Drug Conjugates Reshape Blood Cancer Treatment
A new review synthesizes the clinical evidence, toxicity profiles and resistance mechanisms behind six FDA-approved antibody-drug conjugates for blood cancers.
Immunotherapy Safety Data May Not Apply to Borderline Resectable Lung Cancer
A narrative review argues that safety data from six phase 3 immunotherapy trials in resectable lung cancer may not transfer ...
Cysteine Cathepsins Mapped Across Breast Tumors Reveal States That May Shape Antibody-Drug Conjugate Use
A single-cell and spatial atlas of 66 breast tumors shows cysteine cathepsins occupy specific immune, epithelial and stromal niches, and ...
Patent map reveals the hidden knowledge hubs driving antibody-drug conjugate innovation
A machine-learning analysis of 6,620 ADC patent families identifies 47 technological topics and ten central knowledge hubs spanning targets, payloads, ...
T-DM1 Shows Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer
A single-center study of 21 patients found that trastuzumab emtansine produced no responses and a median progression-free survival of 2.20 ...
Two breast cancer drugs match on progression control, but only one shows a survival benefit
An indirect comparison finds sacituzumab govitecan and datopotamab deruxtecan comparable in progression control, but only sacituzumab govitecan has direct randomized ...
Computational agent pinpoints ADAM17 as drug target in biliary tract cancer
An AI-driven target discovery framework ranked ADAM17 first for biliary tract cancer, and antibody-drug conjugates and CAR-T cells built against ...
Antibody-Drug Conjugates Extend Survival in Triple-Negative Breast Cancer, Meta-Analysis Finds
A systematic review and meta-analysis of six studies covering 2,479 patients found that antibody-drug conjugates significantly improved progression-free and overall ...
VCU grant funds study of TROP2-targeted drugs in breast and pancreatic cancers
A five-year National Cancer Institute grant will fund laboratory research into response biomarkers and resistance mechanisms for TROP2-targeted antibody-drug conjugates ...
POPULAR NEWS
-
Astrocytic IL-17A Drives Blood Vessel Repair Following Stroke-Like Brain Injury
-
SWEET Genes Regulate Development and Stress Responses in Cunninghamia lanceolata
-
Fermented Fish Isolates Show Resilience and Safety in Laboratory Probiotic Screening
-
Multimodal AI Detects Prestressed Concrete Beam Defects in Controlled Laboratory Tests